RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 133 filers reported holding RECURSION PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is 0.76 and the average weighting 2.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $819,239 | +3.0% | 107,090 | +0.5% | 0.00% | – |
| Q2 2023 | $795,630 | +0.1% | 106,510 | -10.7% | 0.00% | – |
| Q1 2023 | $795,164 | +131.1% | 119,215 | +167.2% | 0.00% | – |
| Q4 2022 | $344,020 | -28.0% | 44,620 | -0.7% | 0.00% | – |
| Q3 2022 | $478,000 | +32.4% | 44,952 | +1.5% | 0.00% | – |
| Q2 2022 | $361,000 | +12.8% | 44,283 | -0.8% | 0.00% | – |
| Q1 2022 | $320,000 | -57.0% | 44,633 | +2.7% | 0.00% | – |
| Q4 2021 | $745,000 | +263.4% | 43,473 | +674.6% | 0.00% | – |
| Q2 2021 | $205,000 | – | 5,612 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Data Collective IV GP, LLC | 5,941,120 | $45,806,035 | 48.11% |
| Kinnevik AB (publ) | 7,653,061 | $59,005,100 | 33.28% |
| MV Management XI, L.L.C. | 1,971,908 | $15,203,411 | 26.45% |
| MIC Capital Management UK LLP | 8,451,758 | $65,163,057 | 12.86% |
| ArchPoint Investors | 1,114,626 | $8,593,766 | 4.07% |
| HARVARD MANAGEMENT CO INC | 1,509,254 | $11,636,348 | 1.44% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,710,339 | $20,896,714 | 0.80% |
| Duquesne Family Office | 1,385,950 | $10,685,675 | 0.53% |
| ALLEN OPERATIONS LLC | 217,657 | $1,678,135 | 0.45% |
| Artal Group S.A. | 960,204 | $7,403 | 0.41% |